BioCentury
ARTICLE | Company News

OSI, Wyeth-Ayerst deal

February 2, 1998 8:00 AM UTC

Wyeth-Ayerst exercised its option under a 1992 research agreement with OSIP for an exclusive worldwide license to develop small molecule, gene transcription-based compounds that modulate the expressio...